ABSTRACT OF THE DISCLOSURE

A new class II cytokine receptor has been identified, which comprises an interleukin-22 receptor molecule, and an interleukin-20 receptor β molecule. The complex binds to cytokines homologous to IL-10, including mda-7 and IL-20. Also described are methods for inhibiting effect of interleukin-22 and/or interleukin-20 on cells. The latter is especially useful in treatment of, e.g., skin diseases such as psoriasis.